Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized- Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women
2022
Oliveira, Marília Santini | Pinto, Patrícia Machado | Santos, Tatiane dos | Vilar, Mônica Magno | Grinsztejn, Beatriz | Veloso, Valdiléa G. | Almeida, Elan C. Paes de | Amaral, Maria A. Z. | Ramos, Celso R. | Marroquin-Quelopana, Miryam | Coler, Rhea | Reed, Steven | Ciol, Marcia A. | Savino, Wilson | Parra, Juçara de Carvalho | Almeida, Marília Sirianni dos Santos | Tendler, Miriam
We report the successful closure of Phase I clinical trials, comprising Phases Ia and Ib, of the vaccine candidate against human schistosomiasis: the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE). Shown here are the results of Phase Ib, an open, non-placebo-controlled, standardized-dose immunization trial involving 10 healthy 18–49-year-old women. Fifty micrograms of the Sm14 protein plus 10 g GLA-SE per dose was given intramuscularly thrice at 30-day intervals. Participants were assessed clinically, biochemically, and immunologically for up to 120 days. In preambular experiments involving vaccinated pregnant female rabbits, we did not find any toxicological features in either the offspring or mothers, and the vaccine induced adaptive immunity in the animals. In women, no adverse events were observed, and vaccination induced high titers of anti-Sm14 serum IgG antibody production. Vaccination also elicited robust cytokine responses, with increased TNF , IFN , and IL-2 profiles in all vaccinees on days 90 and 120. The completion of Phase I clinical trials, which were performed to the highest standards set by Good Clinical Research Practice (GCP) standards, and preclinical data in pregnant rabbits enabled the vaccine candidate to proceed to Phase II clinical trials in endemic areas.
显示更多 [+] 显示较少 [-]